Pyxis Oncology Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 56

Employees

  • Stock Symbol
  • PYXS

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.81
  • (As of Friday Closing)

Pyxis Oncology General Information

Description

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 321 Harrison Avenue
  • 11th Floor, Suite 1
  • Boston, MA 02118
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 321 Harrison Avenue
  • 11th Floor, Suite 1
  • Boston, MA 02118
  • United States
+1 (617)

Pyxis Oncology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pyxis Oncology Stock Performance

As of 20-Nov-2026, Pyxis Oncology’s stock price is $1.81. Its current market cap is $216M with 120M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.81 $1.68 $1.03 - $5.55 $216M 120M 1.06M -$1.27

Pyxis Oncology Financials Summary

As of 30-Sep-2026, Pyxis Oncology has a trailing 12-month revenue of $11M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 179,177 14,421 (31,511) (31,568)
Revenue 11,038 13,858 16,146 0
EBITDA (83,500) (77,334) (83,552) (78,493)
Net Income (86,708) (79,621) (77,331) (73,790)
Total Assets 76,770 91,520 157,181 173,726
Total Debt 17,400 18,673 20,200 21,331
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pyxis Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pyxis Oncology‘s full profile, request access.

Request a free trial

Pyxis Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Pyxis Oncology‘s full profile, request access.

Request a free trial

Pyxis Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors,
Drug Discovery
Boston, MA
56 As of 2025

London, United Kingdom
 

San Diego, CA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pyxis Oncology Competitors (51)

One of Pyxis Oncology’s 51 competitors is Akari Therapeutics, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akari Therapeutics Formerly VC-backed London, United Kingdom
Nascent Biotech Corporation San Diego, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Immunophotonics Private Equity-Backed Saint Louis, MO
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 51 competitors. Get the full list »

Pyxis Oncology Patents

Pyxis Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226947-A1 Constructs, compositions, and methods for treating pd(l)1 resistant diseases and disorders Pending 24-Apr-2025
WO-2026112135-A1 Constructs, compositions, and methods for treating diseases and disorders expressing extra domain b splice variant of fibronectin Pending 19-Nov-2024
AU-2025247255-A1 Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders Pending 29-Mar-2024
WO-2025208105-A1 Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders Pending 29-Mar-2024
AU-2024312447-A1 Anti-klrg1 antibodies and uses thereof Pending 23-Jun-2023 C07K16/2851
To view Pyxis Oncology’s complete patent history, request access »

Pyxis Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pyxis Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pyxis Oncology‘s full profile, request access.

Request a free trial

Pyxis Oncology Investments & Acquisitions (2)

Pyxis Oncology’s most recent deal was a Merger/Acquisition with Apexigen for . The deal was made on 23-Aug-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Apexigen 23-Aug-2023 Merger/Acquisition Drug Discovery
Kyma Therapeutics 25-May-2021 Joint Venture Drug Discovery
To view Pyxis Oncology’s complete investments and acquisitions history, request access »

Pyxis Oncology ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.41 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Pyxis Oncology’s complete esg history, request access »

Pyxis Oncology FAQs

  • When was Pyxis Oncology founded?

    Pyxis Oncology was founded in 2018.

  • Where is Pyxis Oncology headquartered?

    Pyxis Oncology is headquartered in Boston, MA.

  • What is the size of Pyxis Oncology?

    Pyxis Oncology has 56 total employees.

  • What industry is Pyxis Oncology in?

    Pyxis Oncology’s primary industry is Drug Discovery.

  • Is Pyxis Oncology a private or public company?

    Pyxis Oncology is a Public company.

  • What is Pyxis Oncology’s stock symbol?

    The ticker symbol for Pyxis Oncology is PYXS.

  • What is the current stock price of Pyxis Oncology?

    As of 20-Nov-2026 the stock price of Pyxis Oncology is $1.81.

  • What is the current market cap of Pyxis Oncology?

    The current market capitalization of Pyxis Oncology is $216M.

  • What is Pyxis Oncology’s current revenue?

    The trailing twelve month revenue for Pyxis Oncology is $11M.

  • Who are Pyxis Oncology’s competitors?

    Akari Therapeutics, Nascent Biotech, Kite Pharma, Immunophotonics, and ORIC Pharmaceuticals are some of the 51 competitors of Pyxis Oncology.

  • What is Pyxis Oncology’s annual earnings per share (EPS)?

    Pyxis Oncology’s EPS for 12 months was -$1.27.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process